---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-009208"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:55:59.485812+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals appoints Rami Levin as CEO effective January 1, 2026; John Climaco resigns

## Summary
- Rami Levin becomes CEO and President effective Jan 1, 2026; base salary $580,000, target bonus 50% of base, initial RSU grant of 19,000 shares.
- John Climaco resigned as CEO and board member Dec 16, 2025; resignation not due to disagreement; severance includes 12 months salary and $319,000 bonus.
- Levin will also join the board; previously CEO of Saniona (2019-2022) and ImStem Biotechnology (2022-2024).
- If Levin is terminated without cause or for good reason, severance includes 12 months base salary, target bonus, accelerated equity vesting, and COBRA subsidy.

## SEC filing metadata
- accession: 0001683168-25-009208
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316825009208/0001683168-25-009208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316825009208/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-009208
- JSON: https://secwatch.observer/filing/0001683168-25-009208.json
- Plain text: https://secwatch.observer/filing/0001683168-25-009208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.